Biosimilars are subsequent versions of an innovator product and have gained popularity over the last 30 years. This series explores the role of biosimilars, addressing the benefits and challenges of creating them and how they have gained momentum within the pharmaceutical industry, with BioAgilytix’s Global CSO, Dr. Afshin Safavi, and other key figures from pharma, CROs, biotech and academia.
Click for full article
Services
Platforms